<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785250</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-DPX-Survivac-06</org_study_id>
    <secondary_id>DeCidE1</secondary_id>
    <nct_id>NCT02785250</nct_id>
  </id_info>
  <brief_title>Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc. (IMV Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc. (IMV Inc.)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor
      epacadostat will be tested together for the first time in patients with recurrent ovarian,
      fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating
      activity of the combination of these agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1b component is a multicenter, non-randomized, open label, uncontrolled, safety and
      effectiveness study to identify the recommended Phase 2 dose (R2PD) of epacadostat in
      combination with DPX-Survivac and cyclophosphamide.

      The Phase 2 component was initially a multicenter, randomized, open-label study to evaluate
      the safety and effectiveness of DPX-Survivac + cyclophosphamide with or without the RP2D of
      epacadostat. The design of the study has been amended to a single arm study in which up to 16
      evaluable subjects will be enrolled to received DPX-Survivac plus intermittent low dose
      cyclophosphamide (i.e. treatment arm 2).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse event reporting (CTCAE)</measure>
    <time_frame>up to 13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (Phase 2 only)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Evaluated using modified RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (for each treatment group)</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Evaluated using modified RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell mediated immunity as measured by the antigen specific response in peripheral blood</measure>
    <time_frame>bimonthly for up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment-induced changes in tumor infiltrating lymphocytes</measure>
    <time_frame>at 8 to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Recurrent Epithelial Ovarian Cancer</condition>
  <condition>Recurrent Fallopian Tube Cancer</condition>
  <condition>Recurrent Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Cyclophosphamide (in Phase 2 only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SubQ injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat (INCB024360)</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically confirmed, stage IIc-IV epithelial ovarian, fallopian tube or
             peritoneal cancer

          -  Platinum-resistant or -sensitive subjects after completing first-line treatment
             (debulking surgery and adjuvant or neoadjuvant treatment with standard of care
             treatment such as carboplatin and paclitaxel). Subjects may have had any number of
             subsequent lines of chemotherapy.

          -  Must have evidence of progressive disease with either biochemical (i.e. rising CA-125)
             and/or radiologic progression

          -  Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy,
             and be willing to undergo tumor biopsy during treatment

          -  Ambulatory with an ECOG 0-1

          -  Life expectancy ≥ 6 months

          -  Meet protocol-specified laboratory requirements

        Key Exclusion Criteria:

          -  Eligible for otherwise curative treatment or undergoing concurrent therapy

          -  Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g.
             anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically
             targeting T cell co-stimulation) or an IDO inhibitor

          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
             in situ, or controlled bladder cancer

          -  Clinical ascites

          -  Any single lesion greater than or equal to 4 cm (per RECIST v1.1)

          -  Malignant bowel obstruction

          -  History of autoimmune disease requiring treatment within the last two years (except
             vitiligo or diabetes)

          -  Recent history of thyroiditis

          -  Presence of a serious acute infection or chronic infection

          -  Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)

          -  GI condition that might limit absorption of oral agents

          -  Other serious intercurrent chronic or acute illness, including myocardial infarction
             or cerebrovascular event within 6 months

          -  Ongoing treatment with steroid therapy or other immunosuppressive

          -  Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors

          -  Receipt of live attenuated vaccines

          -  Acute or chronic skin and/or microvascular disorders

          -  Edema or lymphedema in the lower limbs &gt; grade 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University, Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell activation</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>ovarian</keyword>
  <keyword>fallopian tube</keyword>
  <keyword>peritoneal</keyword>
  <keyword>cancer</keyword>
  <keyword>recurrent</keyword>
  <keyword>tumor</keyword>
  <keyword>measurable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

